Cendo is primarily engaged in pharmaceutical preparations activity. Its headquarters is located in Jawa Barat. The company was founded in 1998. Cendo is a prominent player in the pharmaceutical industry, particularly known for its specialization in ophthalmic products. The company was founded by a group of visionary entrepreneurs with a mission to improve eye health through innovative solutions. Cendo's primary business line is the development and manufacturing of eye care products, while it also engages in secondary activities related to general pharmaceutical preparations. The company has established a strong local presence with several branches across Indonesia, ensuring accessibility to its products nationwide. Cendo's product portfolio includes a wide range of ophthalmic solutions, such as eye drops, ointments, and other eye care treatments. Some of its well-known brands include Cendo Xitrol, Cendo Fenicol, and Cendo Lyteers, which are trusted by healthcare professionals and patients alike. While Cendo primarily operates within Indonesia, it has also expanded its reach to select international markets, exporting its products to neighboring countries in Southeast Asia. The company collaborates with various healthcare organizations and participates in joint ventures to enhance its research and development capabilities. Cendo is a member of several pharmaceutical and healthcare associations, which helps it stay abreast of industry trends and regulatory changes. The company is committed to maintaining high standards of quality and safety in its products, aligning with its vision to be a leader in the eye care industry. Cendo's mission is to provide innovative and effective solutions for better eye health, contributing to the overall well-being of its customers.
Headquarters
KM 6.7, RT001 RW011
Bandung; West Java;
Postal Code: 40256
Contact Details: Purchase the PT Cendo report to view the information.
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service